Engineered Multispecific Antibodies Innovation Research Report 2024: Patent Trends Show a Noticeable Surge in 2023 with Regeneron, Roche, and Amgen Emerging as the Top Patent Filers

Dublin, Jan. 17, 2025 (GLOBE NEWSWIRE) -- The "Innovation Insights: Engineered Multispecific antibodies" report has been added to ResearchAndMarkets.com's offering.Engineered multispecific antibodies (MsAbs) are innovative therapeutic molecules designed to bind simultaneously to multiple epitopes on the same or different targets. This capability allows them to address complex diseases more effectively than traditional monoclonal antibodies. MsAbs can bridge different cells or target multiple pathways, enha ...